Respiratory syncytial virus immune globulin intravenous (human) receives marketing approval in Canada.
Langley
J M
JM
Dalhousie University.
D002170:Canada; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000191:economics / Q000627:therapeutic use*; D018357:Respiratory Syncytial Virus Infections / Q000628:therapy*; D018113:Respiratory Syncytial Virus, Human / Q000276:immunology*; D014481:United States
D016756:Immunoglobulins, Intravenous; C098685:respiratory syncytial virus immune globulin intravenous